Complete regression of anaplastic astrocytoma by intravenous tumor necrosis factor-alpha (TNFα) after recurrence: A case report
- 30 June 1994
- journal article
- case report
- Published by Elsevier in Surgical Neurology
- Vol. 41 (6), 482-485
- https://doi.org/10.1016/0090-3019(94)90012-4
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinomaCancer, 1990
- In vivo Antitumor Mechanism of Natural Human Tumor Necrosis Factor Involving a T Cell‐mediated Immunological RouteJapanese Journal of Cancer Research, 1989
- A phase I clinical trial of recombinant human tumor necrosis factor given daily for five daysCancer Chemotherapy and Pharmacology, 1989
- A phase I clinical trial of recombinant human tumor necrosis factorCancer, 1988
- Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells.Molecular and Cellular Biology, 1988
- A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.Journal of Clinical Oncology, 1988
- Phase I study of recombinant human tumor necrosis factorCancer Chemotherapy and Pharmacology, 1987
- Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro.Journal of Clinical Investigation, 1987
- PROPOSAL OF STANDARDIZED METHODS AND REFERENCE FOR ASSAYING RECOMBINANT HUMAN TUMOR NECROSIS FACTORJapanese Journal of Medical Science and Biology, 1986
- Tumor Necrosis Factor (TNF)Science, 1985